TSE:ASP Acerus Pharmaceuticals (ASP) Stock Price, News & Analysis → Radical change coming — do this NOW to protect yourself (From Weiss Ratings) (Ad) Free ASP Stock Alerts C$0.36 0.00 (0.00%) (As of 01/26/2023) Add Compare Share Share Today's RangeC$0.36▼C$0.3650-Day RangeC$0.36▼C$0.3652-Week RangeC$0.28▼C$10.00Volume1,250 shsAverage Volume4,719 shsMarket CapitalizationC$2.78 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Acerus Pharmaceuticals alerts: Email Address Ad Weiss RatingsRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and radically change life in America as we know it today. And a Draconian set of technologies that could impose a new kind of financial surveillance in America. Click here to learn more. About Acerus Pharmaceuticals Stock (TSE:ASP)Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. It sells its products through its salesforce in the United States and Canada; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.Read More ASP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASP Stock News HeadlinesMay 25, 2023 | benzinga.comAcerus UpdateApril 8, 2023 | theglobeandmail.comClosing Bell: Acerus Pharmaceuticals Corp flat on Thursday (ASP)January 26, 2023 | finance.yahoo.comIIROC Trading Halt - ASPJanuary 26, 2023 | finance.yahoo.comAcerus Files For CCAA ProtectionDecember 22, 2022 | finance.yahoo.comAcerus Announces New Loan Agreement With First Generation CapitalNovember 18, 2022 | finance.yahoo.comAcerus Pharmaceuticals Third Quarter 2022 Earnings: US$0.54 loss per share (vs US$0.64 loss in 3Q 2021)November 14, 2022 | sfgate.comAcerus: Q3 Earnings SnapshotAugust 3, 2022 | finance.yahoo.comAcerus to Report Q2-2022 Financial Results and Host Investor CallJune 7, 2022 | finance.yahoo.comAcerus Announces Amendment and Restatement of the Promissory Note Related to the Up-Front Fee Payable to Former Serenity SecurityholdersMay 10, 2022 | finance.yahoo.comAcerus Reports First Quarter 2022 Financial ResultsApril 27, 2022 | finanznachrichten.deAcerus Pharmaceuticals Corporation: Acerus Announces Completion of Share ConsolidationMarch 10, 2022 | ca.finance.yahoo.comStocks in play: Acerus Pharmaceuticals Corporation.March 10, 2022 | finance.yahoo.comAcerus To Report Q4 And Full Year 2021 Financial Results And Host Investor CallMarch 7, 2022 | stockhouse.comAcerus Announces Closing of Acquisition of Serenity Pharmaceuticals LLC and Acquisition of Global Rights to Noctiva(TM)February 18, 2022 | finance.yahoo.comAcerus Announces Amendment to Loan FacilitiesJanuary 10, 2022 | finance.yahoo.comAcerus Pharmaceuticals Announces Commercial Agreement With Verity Pharmaceuticals for the Promotion of NATESTO® in Puerto RicoDecember 13, 2021 | finance.yahoo.comAcerus Announces Amendments to Loan FacilitiesNovember 2, 2021 | finance.yahoo.comAcerus to Report Q3-2021 Financial Results and Host Investor CallOctober 26, 2021 | finance.yahoo.comResearch Reports Initiated on Healthcare Stocks Nuvo Pharmaceuticals, Acerus Pharmaceuticals, and AvivagenSeptember 9, 2021 | finance.yahoo.comEven with Acerus Pharmaceuticals Corporation (TSE:ASP) stock down 11% this week, insiders who bought recently netted around US$102kAugust 21, 2021 | barrons.comAcerus Pharmaceuticals Corp.August 12, 2021 | finance.yahoo.comAcerus Reports Acceptance of Part 36 Settlement Offer in Recipharm LitigationAugust 3, 2021 | finance.yahoo.comAcerus to Report Q2-2021 Financial Results and Host Investor CallSee More Headlines Receive ASP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:ASP CUSIPN/A CIKN/A Webwww.aceruspharma.com Phone416-679-0771FaxN/AEmployees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($4.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-28,080,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-54.10% Debt Debt-to-Equity Ratio261.01 Current Ratio0.67 Quick Ratio0.26 Sales & Book Value Annual SalesC$3.04 million Price / Sales0.91 Cash FlowC$0.11 per share Price / Cash Flow3.29 Book ValueC($1.80) per share Price / Book-0.20Miscellaneous Outstanding Shares7,710,000Free FloatN/AMarket CapC$2.78 million OptionableNot Optionable Beta1.03 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Edward GudaitisPres, CEO & DirectorMr. Gavin DamstraSr. VP of International CommercialDr. Christopher Sorli F.A.C.E.M.D., Ph.D., Chief Medical OfficerMr. Kevin Thomas HickeySr. VP of US CommercialMr. Naveed ManzoorInterim Chief Financial OfficerMr. Chris WittyInvestor RelationsMr. Philippe SavardSr. VP, Gen. Counsel & Corp. Sec.Mr. Hubert Tomasz CzerwinskiPres of Acerus Pharmaceuticals SRLMore ExecutivesKey CompetitorsMedicureCVE:MPHFlowrCVE:FLWRVoyageur PharmaceuticalsCVE:VMKhiron Life SciencesCVE:KHRNValeo PharmaTSE:VPHView All Competitors ASP Stock Analysis - Frequently Asked Questions How have ASP shares performed in 2024? Acerus Pharmaceuticals' stock was trading at C$0.36 at the start of the year. Since then, ASP shares have increased by 0.0% and is now trading at C$0.36. View the best growth stocks for 2024 here. What other stocks do shareholders of Acerus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acerus Pharmaceuticals investors own include Aurora Cannabis (ACB), Surna (SRNA), Allena Pharmaceuticals (ALNA), Molecular Templates (MTEM), Avid Bioservices (CDMO), OHR Pharmaceutical (OHRP), Trilogy International Partners (TRL), Absolute Software Co. (ABT.TO) (ABT), Ampliphi Biosciences (APHB) and Algonquin Power & Utilities (AQN). How do I buy shares of Acerus Pharmaceuticals? Shares of ASP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:ASP) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredThe Scary Fed Idea To Turn Your Dollars Into a Digital Power GrabCash is becoming a relic of the past… Soon, Biden and the Federal Reserve plan to replace the dollar with t...Oasis Gold | Sponsored"Trump Loophole" Beats InflationThe demise of the "petrodollar" appears imminent. And the implications for Americans could be dire.Colonial Metals | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the ...Crypto 101 Media | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acerus Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acerus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.